SCHEMBL2897227

SCHEMBL2897227

CCOc1cc(O[C@@H]2C[C@@H](C(=O)O)N(C(=O)O)C2)c2cc(Br)c(OC)cc2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 2/20 0.36
HTR3B O95264 2/20 0.36
HTR3A P46098 2/20 0.36
HTR3D Q70Z44 2/20 0.36
HTR3C Q8WXA8 2/20 0.36
ALDH1A1 P00352 4/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
STING1 Q86WV6 2/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
PIK3CD O00329 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CG P48736 2/20 0.31
PIK3CB P42338 1/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 1/20 0.30
TSHR P16473 1/20 0.30
MMP2 P08253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496077 0.87 STING1 (0.35) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL8201734 0.82 P2RX3 (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2892863 0.82 SMN1; SMN2 (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3496484 0.81 HTR3E (0.32) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3496689 0.81 HTR3E (0.32) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3496701 0.81 HTR3E (0.32) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3497308 0.78
SCHEMBL3497319 0.78
Hydrochloric Acid SCHEMBL1071132 0.77 HTR3E (0.37) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL4301154 0.76 APAF1 (0.39) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377874-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-02-19 US disclosed
US-8309540-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-11-13 US disclosed
US-20100286185-A1 HCV NS3 Protease Inhibitors MERCK SHARP & DOHME LLC 2010-11-11 US disclosed
US-20100093779-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093779-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC HTR3E 2559/4885HTR3B 2432/4885HTR3A 2595/4885
US-20100286185-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC HTR3E 2559/4885HTR3B 2432/4885HTR3A 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.